ATAI Life Sciences N.V.: M&A transaction — Atai Beckley completes acquisition of Beckley Psytech, creating AtaiBeckley; issues ~105M shares

ATAI Life Sciences N.V.

Consideration of ~105M new shares issued to Beckley Psytech shareholders, representing ~28% of combined company.
Combined cash expected to fund operations into 2029, through first Phase 3 trial of BPL-003 for TRD.
BPL-003 (mebufotenin benzoate nasal spray) is Phase 3-ready; End-of-Phase 2 FDA meeting scheduled, Phase 3 start Q2 2026.
Board: Christian Angermayer (Chairman), Scott Braunstein (Vice Chairman), Cosmo Feilding Mellen, Robert Hershberg.
Shareholders approved redomiciliation to Delaware; expected completion around year-end 2025.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

ATAI Life Sciences N.V. completed an acquisition involving shareholders of Beckley Psytech for 103,000,066 ordinary shares in atai’s capital (closed 2025-11-05).

Action: acquisition
Counterparty: shareholders of Beckley Psytech
Consideration: 103,000,066 ordinary shares in atai’s capital
Closing: 2025-11-05

Exact text from the filing

Agreement”). In connection with the Acquisition, the Company acquired all of the issued and outstanding equity interests of Beckley Psytech in exchange for an aggregate of 103,000,066 ordinary shares in atai’s capital (“Ordinary Shares”) issued directly as share consideration or as underlying replacement awards pursuant to the Purchase Agreement, which such

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001140361-25-040429

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.